Join

Compare · LMDX vs QTNT

LMDX vs QTNT

Side-by-side comparison of LumiraDx Limited (LMDX) and Quotient Limited (QTNT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both LMDX and QTNT operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
  • LMDX is the larger of the two at $2.23B, about 14.3x QTNT ($156.5M).
  • LMDX has more recent analyst coverage (4 ratings vs 2 for QTNT).
MetricLMDXQTNT
Company
LumiraDx Limited
Quotient Limited
Price
$0.02-53.80%
$0.40+10.10%
Market cap
$2.23B
$156.5M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Exchange
NASDAQ
NASDAQ
IPO
2014
News (4w)
0
0
Recent ratings
4
2
QTNT

Quotient Limited

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ COVID-19 Microarray that is designed as a serological disease screening microarray specific to COVID-19 antibody detection. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.